Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $0.00 | $682K | $55.3M | $175M |
| Revenue growth | — | — | — | — | — | — | 8001.5% | 216.9% |
| Gross profit | — | — | — | — | $0.00 | $515K | $47.3M | $153M |
| Gross margin | — | — | — | — | — | 75.5% | 85.6% | 87.1% |
| Operating income | -$1.23M | -$106M | -$126M | -$135M | -$172M | -$167M | -$277M | -$160M |
| Operating margin | — | — | — | — | — | -24532.6% | -502.2% | -91.4% |
| Net income | -$1.29M | -$255M | -$129M | -$144M | -$198M | -$202M | -$334M | -$221M |
| Net margin | — | — | — | — | — | -29558.9% | -605.1% | -126.3% |
| EPS (diluted) | -$0.21 | -$22.45 | -$3.88 | -$3.89 | -$5.05 | -$3.93 | -$5.29 | -$3.03 |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.02M | -$36.5M | -$69.7M | -$148M | -$147M | -$138M | -$267M | -$167M |
| Capital expenditures | — | $132K | $1.04M | $328K | $1.04M | $1.63M | $135K | $229K |
| Free cash flow | — | -$36.6M | -$70.7M | -$149M | -$148M | -$139M | -$267M | -$167M |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $879K | $244M | $287M | $183M | $155M | $381M | $297M | $130M |
| Total assets | $902K | $257M | $295M | $189M | $165M | $414M | $378M | $259M |
| Total liabilities | $2.19M | $29.2M | $101M | $117M | $240M | $487M | $632M | $697M |
| Long-term debt | — | $22.8M | $39.6M | $89.7M | $95.3M | $138M | $201M | $209M |
| Shareholders' equity | -$1.29M | $228M | $194M | $72.2M | -$74.8M | -$72.8M | -$254M | -$438M |
| Retained earnings | -$1.29M | -$256M | -$385M | -$529M | -$727M | -$929M | -$1.26B | -$1.48B |
| Shares (wtd avg diluted) | — | 24.7M | 28.5M | 37.0M | 39.1M | 51.3M | 63.2M | 72.9M |
Every figure is extracted from Phathom Pharmaceuticals, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.